* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download What is Modeling?
Survey
Document related concepts
Compounding wikipedia , lookup
Plateau principle wikipedia , lookup
Toxicodynamics wikipedia , lookup
Pharmacognosy wikipedia , lookup
List of comic book drugs wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Prescription costs wikipedia , lookup
Prescription drug prices in the United States wikipedia , lookup
Drug interaction wikipedia , lookup
Neuropharmacology wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Drug discovery wikipedia , lookup
Drug design wikipedia , lookup
Transcript
Modeling Data: Methods and Examples Arthur G. Roberts WHAT IS MODELING? Drug Development Discovery Find Targets Phase I 5,000 -10,000 250 Phase 2 Phase 3 FDA Scale-up 5 1 Volunteers 20 -100 3-6 Years $420 million* *Inflation Adjusted Market Clinical Preclinical 100 -500 1,000 -5,000 6-7 Years $585 million* 0.5-2 Total= >$1 billion Innovation.org and DiMasi, et al. 2003 Drug Development Outline • Model Types – PK – PK/PD – Disease Progression – Meta-models and Bayesian Averaging – Population • Estimating Parameters • Simulation Methods • Regulatory Aspects PK models • [drug] versus time • types – compartment PK modeling (CPK) – physiology-based PK modeling (PBPK) PK models: Topology • • • • • • Closed Open Catenary Cyclic Mammillary Reducible PK models: Topology • • • • • • Closed Open Catenary Cyclic Mammillary Reducible [Drug] CPK: Topology • • • • • • Closed [Drug] Open Catenary Cyclic Mammillary Reducible [Drug]out in [Drug] CPK: Topology • • • • • • Closed Open Catenary [Drug] Cyclic Mammillary Reducible Compartment 1 Compartment 2 Compartment 3 [Drug]out in [Drug] [Drug] Chain [Drug] CPK: Topology • • • • • • Closed Open Catenary [Drug] Cyclic Mammillary Reducible Compartment 1 Compartment 2 Compartment 3 [Drug]out in [Drug] [Drug] [Drug] CPK: Topology • • • • • • Closed Open Catenary Cyclic Mammillary Reducible Peripheral Compartment 2 Peripheral Compartment 1 [Drug] [Drug] Central Compartment [Drug] CPK: Topology • • • • • • Closed Open Catenary Cyclic Mammillary Reducible Compartment 2 Compartment 1 [Drug] [Drug] Compartment 3 [Drug] The coupling between the compartments has vastly different dynamics. Simplifies modeling CPK: Topology • • • • • • Brain Closed Open Catenary Cyclic Mammillary Reducible [Drug]Receptor [Drug] Elimination Response Liver CPK: Topology • • • • • • Brain Closed [Drug] Open Catenary [Drug] Cyclic Mammillary Liver Reducible [Drug]Receptor Elimination Response Physiology-Based PK PBPK modeling strategy Examples of Drug Candidate Optimization Areas via PBPK Common Parameters Required ADME Parameters that affect PBPK Where PBPK add value or fail all-trans-retinoic acid (Tretinoin) Pharmacokinetic/Pharmacodynamic (PKPD) • PK + Dose Response Pharmacokinetic/Pharmacodynamic Modelling • Procedure – Estimate exposure – Correlate exposure to PD or other endpoints (e.g. excretion rates) – Use mechanistic models – Model excretion rate as a function of exposure • Purpose – Estimate therapeutic window – Dose selection – Mechanism PD Models • Steady-state • Non-steady state PD models for Steady-State Situations • Fixed effect =Response constant – ototoxicity and gentamycin • Linear model=[drug] proportional to Response • Log-linear model=log[drug] proportional to Response • Emax-model= Concentration-effect (Pharmacodynamic Emax-model) Example Opioid Receptor Agonist PD Models for non-steady state Dose-concentration-effect relationship to be modeled Attributes of PK/PD-models to be considered. Direct Link vs. Indirect Link Direct Response vs. Indirect Response Hard Link vs. Soft Link Selected PK/PD-approach Time invariant vs. Time variant Direct link versus indirect link Direct Link Brain Plasma Elimination [Drug] [Drug] Relative concentrations between the the plasma and the brain remain relatively constant despite the system not being in steady-state. Indirect Link Exhibit hysteresis Distribution delay Indirect Link: Hysteresis Counter-clockwise Clockwise Potential Causes • Distribution Delay • Active metabolite • Sensitization Potential Causes • FunctioTolerance Cocaine and Functional Tolerance Cocaine Other examples: Capsaicin S-Ibuprofen and time delay S-ibuprofen Definition EP=Evoked Potential An evoked potential or evoked response is an electrical potential recorded from the nervous system of a human or other animal following presentation of a stimulus, as distinct from spontaneous potentials as detected by electroencephalography (EEG), electromyography (EMG), or other electrophysiological recording method. Direct Response versus Indirect Response • Direct Response – no time lag like indirect link (hysteresis?) • Indirect Response (hysteresis?) Drug Effect Indirect Response Lymphocytes [drug]P fluticasone Soft link versus Hard Link • • Soft link – PK+PD data – temporal delay – Indirect link models are soft link because they must be characterized using PK and PD data. Hard link – PK data + in vitro studies (e.g. binding affinities) Time variant versus time invariant • Tolerance – Functional or PD tolerance (Hysteresis?) • Sensitization (Hysteresis) Disease Progression Models • 1992 – Alzheimer’s via Alzheimer Disease Assessment Scale (ADASC) • Characteristics – Subject variability – Correlated to PK model – Drug effects Meta-models and Bayesian averaging • Meta-analyses means “the analysis of analyses” • Bayesian averaging – Thomas Bayes (1702-1761) – Biased averaged based on other information – Method to average several different models Population Models • Data and database preparation • Structural models – algebraic equations – differential equations • Linearity and superposition • Stochastic models for random effects • Covariate models for fixed effects Population Models: Data and database preparation • • • • only good as the data in them accuracy (remove errors) data consistency remove significant outliers Population Models: Structural Models • Structural model = Structural equation modeling (SEM) • Algebraic and Differential Population Models: Linearity and superposition • Linearity – Linear with respect to parameters (i.e. directly correlated) – Equation doesn’t have to be linear • Superposition – additive – dose 1 + dose 2 = doses together dose 3 dose 2 dose 1 [Drug] Population Models: Stochastic Models for Random Effects • Variability – low therapeutic index high probability of subtherapeutic and toxic exposure – Residual unexplained variability (RUV) • Observation value – Model predicted value – Between subject variability (BSV) – 1 level-linear regressiion – Multi-level-hierarchies Population Models: Covariate models for fixed effects • Covariates- Something that causes variation. • Fixed effect- parameter estimated from an average or an equation and not estimated from data (no BSV) Variability and Covariates Estimating Parameters • Least Squares – slope and intercept values – residues=Value-Average Value – least squares= Sum of (Value-Average Value)^2 • Weights – least squares weighted toward high data points • Objective Function Value (OFV) – negative log sum of likelihoods – minimum value = best fit • Parameter Optimization – used because PK has too many variables Parameter Optimization Examples • • • • Evolutionary Programming Genetic Algorithm Simulated Annealing Random Searching Simulation Methods • Validation – internal – subset of the data – external – new data set • Extrapolation – simulating data outside the observed data set • Limitations and Assumptions • Non-Stochastic Simulations (simple fitting) • Stochastic Simulations – Random-effect parameters (e.g. Population Variability) • simulated with a random number generator based on a distribution – Model simulated repeatedly Stochastic Simulations: Simulated doses to different groups Simulation Software • Proprietary – PK-Sim 5 – Pheonix WinNonlin • Freeish – Monolix • http://www.lixoft.eu/products/monolix/product-monolixoverview/ – Excel • Open Source or Free – http://www.pharmpk.com/soft.html • JavaPK for Desktop Regulatory Aspects • FDA Modernization Act of 1997 – exposure-response with a single clinical trial = effectiveness – Population modeling • identify sources of variability safety and efficacy • Personalized Medicine – Cost effective – Modeling critical • Optimize doses – Pharmacogenetics • Warfarin exposure and response dependent on CYP2C9 genotrype END OF MODELING DATA AND EXAMPLES